CELTA: Hypertonic Saline Resuscitation in Trauma Patients After Hemorrhage Control

Sponsor
Fundacion Clinica Valle del Lili (Other)
Overall Status
Terminated
CT.gov ID
NCT02542241
Collaborator
(none)
52
1
2
33.2
1.6

Study Details

Study Description

Brief Summary

This study aimed to determine whether hypertonic saline solution is effective in the resuscitation of injured patients undergoing abdominal damage control surgery regarding early closure of the abdominal wall.

Condition or Disease Intervention/Treatment Phase
  • Drug: Sodium Chloride [3%]
  • Drug: Sodium Chloride [0.9%]
Phase 4

Detailed Description

A double-blind, controlled, randomized clinical trial was conducted to determine the impact of an infusion of hypertonic saline 3% vs. isotonic saline 0.9% at a dose of 50 mL/hr for the first 72 hours in patients with abdominal trauma requiring damage control surgery regarding some clinically relevant outcomes. These outcomes were: The timing of abdominal cavity closure, fluids balance, abdominal hypertension, and abdominal compartment syndrome occurrence, organ dysfunction, and 28 days' mortality.

Study Design

Study Type:
Interventional
Actual Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Hypertonic Saline Resuscitation for Early Closure of Open Abdomen in Trauma Patients
Study Start Date :
Nov 27, 2015
Actual Primary Completion Date :
Sep 4, 2018
Actual Study Completion Date :
Sep 4, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sodium Chloride [3%]

Drug: Sodium Chloride [3%]
Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Other Names:
  • Hypertonic Saline Solution
  • NaCl
  • Active Comparator: Sodium Chloride [0.9%]

    Drug: Sodium Chloride [0.9%]
    Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
    Other Names:
  • Physiologic Saline Solution
  • Normal Saline
  • Outcome Measures

    Primary Outcome Measures

    1. Abdominal wall closure [7 days]

      Proportion of patients in which closure of abdominal wall was achieved in the first 7 days after injury.

    Secondary Outcome Measures

    1. Fluid Balance measured in cm3 [72 hours]

      Fluid balance during the first 72 hours after injury. Defined as the difference between the amount of fluids taken into the body and the amount excreted or lost. Input includes oral fluids, infused intravenous fluids and blood products. Output includes fluid loss as urine, emesis and wound drainage among others.

    2. Incidence of Abdominal compartment syndrome [7 days]

      Incidence of abdominal compartment syndrome (defined as sustained intra-abdominal pressure > 20 mmHg, accompanied by new organ dysfunction, defined as a score > 2, under the SOFA scale compromising lung, kidney, or heart) during the first 7 days after injury.

    3. Incidence of Organ Failure [7 days]

      Incidence of organ failure (defined as SOFA score greater than 2).

    4. Mortality [28 days]

      28 day mortality rate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Abdominal trauma requiring damage control surgery.

    • Acceptance by the patient or by a proxy to be included in the trial.

    Exclusion Criteria:
    • Concomitant severe head trauma, defined by a Glasgow score <9, before receiving sedation or by the presence of cerebral edema or intracranial injury on a CT-scan.

    • Pregnancy

    • Patient not included 4 hours or more after damage control surgery.

    • Damage control laparotomy performed for other indications other than trauma.

    • Not index damage control laparotomy

    • No acceptance to participate in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fundacion Clinica Valle del Lili Cali Valle Del Cauca Colombia

    Sponsors and Collaborators

    • Fundacion Clinica Valle del Lili

    Investigators

    • Principal Investigator: Alberto F García, MD, Fundacion Clinica Valle del Lili

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alberto Federico García, MD., Fundacion Clinica Valle del Lili
    ClinicalTrials.gov Identifier:
    NCT02542241
    Other Study ID Numbers:
    • 00877
    First Posted:
    Sep 4, 2015
    Last Update Posted:
    Jun 11, 2020
    Last Verified:
    Jun 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Alberto Federico García, MD., Fundacion Clinica Valle del Lili
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 11, 2020